胶质母细胞瘤 (GBM) 是一种极为侵袭性的恶性脑肿瘤，目前缺乏有效的治疗方法。受最近细胞膜仿生纳米载体技术进展的启发和巨噬细胞在 GBM 病理学中的关键作用的影响，我们开发了巨噬细胞膜脂质体 (MML) 用于 GBM 靶向。首次评估了巨噬细胞极化状态在这些药物输送系统的有效性中的作用。有趣的是，我们观察到，M2 巨噬细胞来源的 MML (M2 MML) 相比 M1 巨噬细胞来源的纳米载体 (M1 MML) 和对照脂质体 (CL)，表现出更高的摄取率和增加的抗癌药物阿霉素的释放。此外，巨噬细胞对 MML 的吸收最低，显示出良好的免疫逃逸特性。值得注意的是，M2 巨噬细胞揭示了更高的整合素 CD49d 表达，这是与肿瘤细胞之间的双向通讯有关的关键蛋白质。因此，我们的研究结果表明，使用 M2 巨噬细胞膜开发针对 GBM 的新型纳米载体具有潜力。版权所有 ©2023 Elsevier Inc.发表。

Glioblastoma (GBM) is a highly aggressive malignant brain tumor currently without an effective treatment. Inspired by the recent advances in cell membrane biomimetic nanocarriers and by the key role of macrophages in GBM pathology, we developed macrophage membrane liposomes (MML) for GBM targeting. For the first time, it was assessed the role of macrophage polarization states in the effectiveness of these drug delivery systems. Interestingly, we observed that MML derived from M2 macrophages (M2 MML) presents higher uptake and increased delivery of the anticarcinogenic drug doxorubicin compared to M1 macrophage-derived nanocarriers (M1 MML) and control liposomes (CL). Moreover, the lowest uptake by macrophages of MML reveals promising immune escaping properties. Notably, M2 macrophages unveiled a higher expression of integrin CD49d, a crucial protein involved in the bilateral communication of macrophages with tumor cells. Therefore, our findings suggest the potential of using M2 macrophage membranes to develop novel nanocarriers targeting GBM.Copyright © 2023. Published by Elsevier Inc.